ASCO annual meeting featured a urothelial carcinoma oral abstract session and a discussant presentation by Dr. John Sfakianos ...

We know from the phase 2 TROPHY-U-01 trial that sacituzumab govitecan is an active drug, with an objective response rate of ...

Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute, located in Orlando, Florida. At the moment … we really cannot institute Opdivo plus Yervoy, since it's not going to be ...

Just like humans, dogs can also get urinary tract infections (UTIs). A healthy dog has a sterile bladder, but a UTI often ...

UC Davis Comprehensive Cancer Center is testing a drug called niraparib (ZEJULA), given before prostate cancer surgery.

§ Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China ∥ Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, China *(Zheng Li) E-mail: [email protected ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder ...

The company is developing a breath-based early detection test for multiple types of cancer — one that involves dogs and their powerful noses. The test uses AI and trained canines to analyze ...

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD. Data presented at the 2025 American Urological Association (AUA) Annual Meeting ...

Up to 40% of patients with bladder cancer have renal impairment, defined as a creatinine clearance ≤60 ml/min, as calculated by the Cockroft–Gault formula. [13] Renal insufficiency may be ...